|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Peripheral blood LRP expression as well as marrow and blood MDR1 and MRP2 expression have no predictive value in AML patients treated with standard dose cytarabine and daunorubicin 3+7 regimen.
|
30674943 |
2019 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High BCL11A and MDR1 expression was associated with a poor response to chemotherapy, and identified a subset of AML patients with a very poor prognosis.
|
29469608 |
2018 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subset of virus-specific CD161<sup>+</sup> T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.
|
27821506 |
2017 |
|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype.
|
25155901 |
2014 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NBDHEX is not a substrate of either MDR1-Pgp or MRP1 efflux pumps; in fact, it is not only cytotoxic toward the parental HL60 cell line, but also overcomes the MDR phenotype of its HL60/DNR and HL60/ADR variants.
|
19288261 |
2009 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients.
|
18001833 |
2008 |
|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the potential involvement of the ABCB1 gene exon 26 3435C>T single nucleotide polymorphism (SNP) in the genetic susceptibility to AML and regulation of P-gp expression and activity in AML cells.
|
17038891 |
2006 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delineation of the adverse prognostic power of MDR1 in adult acute myeloid leukemia (AML) raised hopes that pharmacologic blockade of P-gp would improve the outcome of conventional cytotoxic therapy, perhaps more so than in any other human malignancy.
|
15217827 |
2004 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.
|
15109536 |
2004 |
|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results reported above show that FLT3 mutations and MDR1 expression represent two independent clinical prognostic factors for AML patients.
|
12926083 |
2003 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present results suggest that BCRP, but not MDR1, MRP1 or LRP/MVP is associated with clinical resistant disease in AML.
|
11986944 |
2002 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Looking at specific cytogenetic aberrations significantly more mdr1 positive AML patients were found within t(8;21), +8, +21, del(7q), del(5q), -7, abn(3q) and multiple aberrations.
|
12010657 |
2002 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of leukaemic cell lines and 50 AML patient samples showed that the level of P-gp mRNA or total P-gp protein correlated better with drug efflux than surface P-gp protein, suggesting that intracellular P-gp may contribute to MDR in AML.
|
11301107 |
2001 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Data compared prior to and after therapy start (paired samples) revealed that AML patients who did not respond to therapy (NR) expressed increased levels of mdr-1 mRNA, as well as MRP and bcl-2 cDNA normalized to GAPDH reference transcripts, when compared to patients achieving complete remission (CR; p = 0.003, 0.008 and 0.0005, respectively).
|
10500792 |
1999 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The failure of convenional chemotherapy in relapsed or refractory and other poor risk AML patients has been linked to expression of the multidrug resistance gene (mdr 1) product P-glycoprotein (P-gp).
|
10500779 |
1999 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts.
|
10374860 |
1999 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The best characterized resistance mechanism in adult acute myeloid leukemia (AML) is the one mediated by the MDR1 gene which has been shown to be associated with poor outcome.
|
10214864 |
1999 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.
|
10233413 |
1999 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This data shows that although MDR-1 can be a relevant parameter in the evaluation of AML patients, larger series of patients using appropriate techniques for specifically analyzing the MDR of blast cells will be necessary in order to establish the final clinical value of this parameter.
|
9368475 |
1997 |
|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AML samples were studied with the MDR1-specific MAbs MRK16 and 4E3, and the efflux function was analyzed using Rh-123 retention in the absence or presence of verapamil.
|
8891227 |
1996 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mdr1 gene or its glycoprotein product, P-glycoprotein, is detected with high frequency in secondary acute myeloid leukemia (AML) and poor-risk subsets of acute lymphoblastic leukemia.
|
1283551 |
1992 |